ANPP (Algeria)

ANPP (the Agence Nationale des Produits Pharmaceutiques) is the People's Democratic Republic of Algeria's autonomous national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + reagents + pharmacy practice + cosmetics + drugs of abuse + pharmaceutical-products + pharmaceutical-industry oversight. ANPP was established under Law 18-11 of 2 July 2018 (Loi Sanitaire — the Health Law modernising the 1985 Loi de Protection et de Promotion de la Santé) + organised by Executive Decree 19-379 of 31 December 2019 + became operational in 2020. ANPP consolidates medicines + pharmaceutical-products regulation previously dispersed across the LNCPP (Laboratoire National de Contrôle des Produits Pharmaceutiques) + the former Direction de la Pharmacie within the Ministry of Health + the regulatory functions of the Ministry of Industrial Pharmaceutical Production.

ANPP is distinctively positioned: it reports to the Ministry of Pharmaceutical Industry (Ministère de l'Industrie Pharmaceutique) — a distinctive Algerian ministerial separation between Health and Pharmaceutical Industry portfolios established in 2020 reflecting Algeria's strategic prioritisation of domestic pharmaceutical industrial development + import-substitution + export-orientation. This ministerial positioning differs from peer regulators (Morocco DMP under Ministry of Health, Tunisia DPM/ANPM under Ministry of Health, SAHPRA under Ministry of Health, EDA under Ministry of Health) + reflects Algeria's industrial-policy approach to pharmaceutical regulation. ANPP maintains technical coordination with the Ministry of Health, Population and Hospital Reform on pharmacovigilance + clinical trials + medical-device matériovigilance + public-health-emergency response.

ANPP's organisational structure includes:

• Directeur Général — chief executive appointed by Presidential Decree; serves at Presidential discretion.
• Conseil d'Administration — governing board with multi-ministerial (Industrie Pharmaceutique, Santé, Finances, Commerce, Travail) + scientific + civil-society representation; approves strategic plan + budget + major regulatory decisions.
• Direction de l'Enregistrement des Médicaments — drug + biological + vaccine + biosimilar + generic-medicine registration via Décision d'Enregistrement procedure.
• Direction des Dispositifs Médicaux + Réactifs — medical-device + IVD + reagent registration + post-market matériovigilance + réactovigilance.
• Direction de l'Inspection — Algerian + foreign manufacturer + distributor + pharmacy GMP/GDP/GPP inspections.
• Direction de l'Information Économique + Tarification — pharmaceutical-price regulation + reimbursement coordination with CNAS (Caisse Nationale des Assurances Sociales) + import-substitution policy support.
• Direction de la Pharmacovigilance + Matériovigilance — Centre National de Pharmacovigilance et de Matériovigilance (CNPM, Algiers) coordination + WHO PIDM coordination.
• Direction Cosmétiques + Produits Parapharmaceutiques — cosmetic + parapharmaceutical-product registration + cosmétovigilance per Law 18-11 cosmetics framework.
• Direction de la Coopération Internationale — international cooperation + WHO + AMRH + AMA + EU + UMA + Arab League + UfM coordination.
• LNCPP (Laboratoire National de Contrôle des Produits Pharmaceutiques, Algiers) — central pharmaceutical QC laboratory; ISO/IEC 17025 accredited + WHO PQ-Lab candidate.
• CNPM (Centre National de Pharmacovigilance et de Matériovigilance, Algiers) — integrated pharmacovigilance + matériovigilance centre operating under ANPP coordination; integrated with toxicovigilance via CNT (Centre National de Toxicologie).
• Commission d'Enregistrement des Produits Pharmaceutiques — scientific advisory commission issuing opinions on registration applications.
• Pharmacie Centrale des Hôpitaux (PCH) — central public-sector pharmaceutical procurement (separate from ANPP regulatory function; sits under Ministry of Health).
• Network of regional pharmacy inspectors coordinated through Direction de la Santé et de la Population in each of Algeria's 58 wilayas.

ANPP is distinct from + complementary to: the Ministry of Pharmaceutical Industry broader Directorates; the Ministry of Health, Population and Hospital Reform broader Directorates (Direction Générale de la Prévention et de la Promotion de la Santé, Direction Générale des Services de Santé); the Conseil National de l'Ordre des Pharmaciens (Order of Pharmacists, pharmacist professional body); the INSP (Institut National de Santé Publique, public-health surveillance + epidemiology); the Institut Pasteur d'Algérie (IPA, biological research + vaccine production + national reference laboratory for selected biologicals); the ANSS (Agence Nationale de Sécurité Sanitaire, public-health emergency response established alongside ANPP in 2020); the Direction Générale des Forêts + the Direction des Services Vétérinaires (veterinary medicines + animal-origin foods); the SAIDAL Group (state-owned pharmaceutical manufacturer + largest Algerian pharmaceutical producer); + the UNOP (Union Nationale des Opérateurs de la Pharmacie, Algerian pharmaceutical industry association). ANPP's institutional environment is characterised by substantial state-owned pharmaceutical manufacturing (SAIDAL) + substantial private generic-medicines manufacturing + strategic import-substitution + export-orientation policies + the largest Maghreb domestic pharmaceutical market + Francophone + EU + Mediterranean + Arab regulatory tradition alignment.

Legal foundations are Law 18-11 of 2 July 2018 (Loi Sanitaire — current organic Health Law replacing Law 85-05 of 1985 Loi de Protection et de Promotion de la Santé); Executive Decree 19-379 of 31 December 2019 (establishing ANPP); Executive Decree 92-284 + successor decrees (pharmaceutical-establishment authorisation framework); Executive Decree 93-114 + successor decrees (pharmacy practice + pharmacy premises licensing); Law 04-18 of 25 December 2004 (controlled substances + narcotics + psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988); Law 09-03 of 25 February 2009 (consumer protection + sanctions for non-compliant pharmaceutical products); + a substantial body of ANPP Décisions + Notes Techniques. Algerian pharmaceutical regulation operates substantively in French (administrative + scientific language) with Arabic (official Constitution language + classical/MSA scientific publication) labelling requirements + selective Tamazight (Constitutional co-official language since 2016) inclusion.

ANPP is a WHO Listed Authority candidate + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority + an AMA (African Medicines Agency) Technical Committee participant + a founding Arab Maghreb Union (UMA) pharmaceutical cooperation partner + a Union for the Mediterranean (UfM) regulatory cooperation partner + an active League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation participant. ANPP holds substantial cooperation arrangements with ANSM France (historic Francophone alignment) + AEMPS Spain + AIFA Italy + PEI Germany + EMA + Morocco DMP + Tunisia DPM/ANPM + Libya NRA + Mauritania DPL + Egyptian EDA + Saudi SFDA + Jordanian JFDA + AMA-positioned for full Continental African coordination.

Algerian pharmaceutical regulation operates under a layered framework of Laws + Executive Decrees + ANPP Décisions + Notes Techniques:

• Law 18-11 of 2 July 2018 — Loi Sanitaire; current organic Health Law replacing Law 85-05 of 1985.
• Executive Decree 19-379 of 31 December 2019 — establishing ANPP as autonomous agency reporting to Ministry of Pharmaceutical Industry.
• Executive Decree 92-284 + successor decrees — pharmaceutical-establishment authorisation framework.
• Executive Decree 93-114 + successor decrees — pharmacy practice + pharmacy premises licensing.
• Law 04-18 of 25 December 2004 — controlled substances + narcotics + psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988; coordinates with INCB.
• Law 09-03 of 25 February 2009 — consumer protection + sanctions for non-compliant pharmaceutical products.
• ANPP Bonnes Pratiques de Fabrication (BPF) — Algerian GMP framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• ANPP Bonnes Pratiques de Distribution (BPD) — Algerian GDP framework substantively aligned with WHO + EU GDP.
• ANPP Bonnes Pratiques Cliniques (BPC) — Algerian GCP framework substantively aligned with ICH E6(R2).
• ANPP Bonnes Pratiques de Pharmacovigilance (BPPv) — Algerian PV framework substantively aligned with ICH E2 + EU GVP.
• Pharmacopée Algérienne — Algerian Pharmacopoeia; recognises European Pharmacopoeia + USP + BP + Pharmacopée Algérienne monographs.
• ANPP Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + AMRH-MDH.
• ANPP Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation + cosmétovigilance.
• ANPP Décisions d'Enregistrement Variations + 5-year Renewal — variations classification + procedures + mandatory 5-year renewal framework.
• Industrial Pharmaceutical Production framework — strategic import-substitution + export-orientation policies coordinated through Ministry of Pharmaceutical Industry.

LNCPP (the Laboratoire National de Contrôle des Produits Pharmaceutiques) is ANPP's central pharmaceutical quality-control laboratory in Algiers + is ISO/IEC 17025 accredited (ALGERAC — Organisme Algérien d'Accréditation) + a WHO Prequalification of Quality Control Laboratories (WHO PQ-Lab) candidate. LNCPP was originally established as an independent laboratory + has been integrated into ANPP under the 2019 establishment framework. WHO PQ-Lab designation would position LNCPP alongside South Africa NCL + Ethiopia NFBMQCL + Tanzania NCQAL + Morocco LNCM + Egypt EDA NODCAR as one of the few WHO-prequalified pharmaceutical QC laboratories in Africa + the Mediterranean basin.

• ISO/IEC 17025 Accreditation — LNCPP is ISO/IEC 17025 accredited (ALGERAC) across multiple testing scopes including pharmaceutical chemical + microbiological + biological testing.
• WHO PQ-Lab Candidate — LNCPP is pursuing WHO PQ-Lab designation; would provide Algeria with WHO-recognised pharmaceutical QC capacity supporting WHO PQ + ANPP regulatory testing + Global Fund + Gavi + UNICEF procurement support.
• AMRH + AFRO Regional Reference Laboratory Candidate — LNCPP positioned for AMRH-coordinated regional reference-laboratory functions for sub-Saharan African + Francophone Africa medicines QC capacity.
• Institut Pasteur d'Algérie (IPA) — Algiers-based biological research + vaccine production + national reference laboratory for selected biologicals; coordinates with LNCPP for vaccine + biological testing.
• Vaccine lot release — LNCPP + IPA conduct vaccine lot-release testing for ANPP + Algerian PNV + selected African vaccine programmes.
• Pharmaceutical pre-registration + post-market testing — LNCPP conducts pre-registration quality testing + post-market surveillance + targeted enforcement testing for ANPP.
• Counterfeit-medicine forensics — LNCPP provides forensic analytical support for ANPP + Direction Générale des Douanes Algériennes investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — LNCPP hosts AMRH + AMA + UMA + Union for the Mediterranean + Council of Arab Ministers of Health capacity-building programmes + training for African + Mediterranean + Arab pharmaceutical analysts.
• GMP Inspectorate support — LNCPP provides scientific + technical support for ANPP GMP inspections of Algerian + foreign manufacturing facilities.
• Pharmacopée Algérienne development — LNCPP contributes to Pharmacopée Algérienne monograph development alongside European + International Pharmacopoeia harmonisation.
• Industrial pharmaceutical-production analytical support — LNCPP provides analytical support to Ministry of Pharmaceutical Industry import-substitution + export-orientation initiatives including SAIDAL + private domestic manufacturers.

ANPP medical-device + IVD + reagent regulation operates under Law 18-11 of 2018 + ANPP Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + AMRH-MDH. Foreign manufacturers must appoint an Algerian Authorised Representative (Représentant Autorisé).

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF + AMRH-MDH; IVDs + reagents classified under separate Algerian IVD/reagent framework.
• Représentant Autorisé Algérien — Algeria-resident legal entity required for foreign manufacturers; bears post-market matériovigilance responsibility + ANPP regulatory interface.
• ISO 13485:2016 — recognised by ANPP as QMS evidence framework; Algerian-specific overlay required including Algerian quality records + Représentant Autorisé QMS interface.
• Reliance pathways — ANPP accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; CE Mark particularly central given francophone + EU regulatory tradition.
• AMRH Medical Devices Harmonisation — ANPP participates in AMRH-MDH work-streams; reliance + harmonised technical-file requirements progressively expanding across African Member States.
• Union for the Mediterranean Medical-Device Cooperation — ANPP participates in UfM medical-device regulatory cooperation alongside EU Mediterranean Member States + Mediterranean Partner Countries.
• Post-market matériovigilance — ANPP operates medical-device adverse-event reporting through the Algerian Matériovigilance System coordinated by CNPM; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Réactovigilance — ANPP operates dedicated IVD + reagent réactovigilance reflecting strong Algerian clinical-laboratory infrastructure.
• Cosmetic Notification — cosmetics require ANPP Cosmetic Notification + French + Arabic labelling; INCI-aligned ingredient listing + safety substantiation + cosmétovigilance reporting; substantively EU-aligned framework.
• Algerian UDI — ANPP is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Algerian-specific overlay applies.
• Importation Permit — ANPP Importation Permit required in addition to product registration for foreign-manufactured devices entering Algeria; coordination with Direction Générale des Douanes Algériennes.
• Domestic manufacturing priority — Ministry of Pharmaceutical Industry import-substitution policy progressively expanding to medical-device sector; ANPP coordinates prioritised review for Algerian-domestically-manufactured devices.

ANPP operates the Algerian Pharmacovigilance Programme through coordination with CNPM (Centre National de Pharmacovigilance et de Matériovigilance, Algiers). Algeria is a long-standing WHO Programme for International Drug Monitoring (PIDM) member (since 1999) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). CNPM operates Algeria's integrated pharmacovigilance + matériovigilance + réactovigilance + cosmétovigilance centre — an integrated model providing efficient resource use across vigilance functions, with toxicovigilance coordinated through the CNT (Centre National de Toxicologie).

• Centre National de Pharmacovigilance et de Matériovigilance (CNPM, Algiers) — integrated pharmacovigilance + matériovigilance + réactovigilance + cosmétovigilance centre operating under ANPP coordination.
• Centre National de Toxicologie (CNT, Algiers) — toxicovigilance + anti-poison-information centre coordinating with CNPM on integrated vigilance.
• WHO PIDM Long-standing Member — Algeria is a WHO PIDM member since 1999 + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Réseau Algérien de Pharmacovigilance — coordinated national pharmacovigilance network with effector centres in major university hospitals (CHU Mustapha Pacha Alger, CHU Bab El Oued Alger, CHU Beni Messous Alger, CHU Constantine, CHU Oran, CHU Annaba, CHU Tlemcen, CHU Batna) + Direction de la Santé et de la Population + Marketing Authorisation Holders.
• Online ADR Reporting — ANPP/CNPM operates online ADR reporting via the CNPM portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — ANPP accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); ANPP-specific submission timeline.
• Risk Management Plans (RMP) — ANPP requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — ANPP/CNPM operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + sentinel-site hospital surveillance through major Algerian CHUs.
• Manifestations Postvaccinales Indésirables (MAPI) — Algerian vaccine adverse-event surveillance aligned with WHO methodology; central to PNV + COVID-19 vaccine safety monitoring (including domestically-produced CoronaVac at SAIDAL during the pandemic).
• Matériovigilance + Réactovigilance + Cosmétovigilance — ANPP/CNPM operates parallel matériovigilance for medical devices + réactovigilance for IVDs/reagents + cosmétovigilance for cosmetics.

• WHO Listed Authority Candidate — ANPP is a WHO Listed Authority candidate based on active WHO PQ CRP participation + LNCPP WHO PQ-Lab trajectory + AMRH co-Reference Authority designation.
• WHO PQ CRP Participating Authority — ANPP is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Candidate — LNCPP is pursuing WHO PQ-Lab designation.
• AMRH co-Reference Authority — ANPP is an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority alongside SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Ethiopia EFDA + Morocco DMP + Tunisia DPM/ANPM.
• AMA Technical Committee Participant — ANPP participates in African Medicines Agency (AMA) Technical Committees under AU Decision Assembly/AU/Dec.857(XXXVII) + Kigali HQ coordination.
• Arab Maghreb Union (UMA) Founding Partner — ANPP is a founding UMA pharmaceutical cooperation partner alongside Morocco DMP + Tunisia DPM/ANPM + Libya NRA + Mauritania DPL; though UMA broadly dormant since 1994 closure of Morocco-Algeria border, pharmaceutical-cooperation channels remain through bilateral coordination.
• Union for the Mediterranean (UfM) Partner — ANPP participates in UfM regulatory cooperation alongside EU Mediterranean Member States (France, Spain, Italy, Portugal, Greece, Cyprus, Malta) + Mediterranean Partner Countries (Morocco, Tunisia, Egypt, Israel, Jordan, Lebanon, Palestine, Turkey).
• League of Arab States Council of Arab Ministers of Health — active pharmaceutical-harmonisation participant alongside Egyptian EDA + Saudi SFDA + Morocco DMP + Tunisia DPM/ANPM + Jordanian JFDA + UAE MoHAP + Lebanese MoH + Kuwait MoH + Bahrain NHRA + others.
• EMA Cooperation — ANPP holds informal cooperation with EMA covering information exchange + reliance + capacity-building; reflects Algeria's francophone + EU-aligned regulatory tradition.
• ANSM France Bilateral — ANPP holds substantial bilateral cooperation with ANSM France reflecting historic Franco-Algerian ties + francophone regulatory alignment; ANSM France provides training + scientific cooperation + expert exchanges.
• AEMPS Spain + AIFA Italy + PEI Germany Bilateral — ANPP holds bilateral cooperation with AEMPS Spain + AIFA Italy + PEI Germany reflecting Mediterranean + EU regulatory cooperation; AEMPS Spain particularly substantial given geographic proximity.
• ICH Observer Candidate — ANPP is positioned for ICH Observer status; ICH guidelines extensively implemented in Algerian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• IMDRF Affiliate Candidate — ANPP is positioned for IMDRF Affiliate status + draws on IMDRF guidance for medical-device regulation.
• PIC/S Pre-Accession Pathway — ANPP is on PIC/S Pre-Accession pathway; BPF framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7.
• Russia Roszdravnadzor + China NMPA Bilateral — ANPP holds bilateral cooperation reflecting Algeria's diversified strategic-partner relationships including BRICS+ cooperation candidacy + Russian-vaccine + Chinese-vaccine + Indian-generic-medicines procurement experience.
• ICDRA + AVAREF participation — active International Conference of Drug Regulatory Authorities + African Vaccine Regulatory Forum (AVAREF) participant.

• Algerian Représentant Autorisé not properly designated — application rejected at ANPP intake or post-approval compliance failure.
• French + Arabic labelling deficiencies — French + Arabic labelling required (with selective Tamazight Constitutional co-official inclusion since 2016); many applicants provide insufficient Arabic-language notice patient or use European French rather than Algerian French terminology.
• BPF gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Algeria-specific ANPP BPF clarifications + Algerian quality records.
• Algerian climate-zone stability data missing — Algeria spans Climate Zone II (Mediterranean coastal Algiers-Oran-Annaba) + Climate Zone IVa-IVb (interior + Saharan southern wilayas covering ~80% of national territory including Tamanrasset, Adrar, Tindouf); many applicants provide insufficient zonal-specific stability data particularly for Saharan distribution.
• Bioequivalence centres + biowaiver — ANPP Biowaiver Guidance provides BCS-based biowaivers + applicants frequently submit BE studies where biowaivers would suffice; alternatively many submit insufficient BE evidence where studies are required.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated ANPP CRP review (90-day target); under-utilised by many applicants.
• AMRH / AMA reliance not leveraged — AMRH co-Reference Authority + AMA Technical Committee reliance pathways under-utilised; provides substantial acceleration for African-Reference-Authority-assessed products.
• EU / EMA / ANSM France reliance under-utilised — ANPP operates strong reliance on EMA + ANSM France + AIFA Italy + AEMPS Spain decisions reflecting Algeria's francophone + Mediterranean alignment; under-utilised by many applicants.
• UMA / Arab League harmonisation not leveraged — UMA pharmaceutical cooperation + Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised for Maghreb + Arab-Reference-Authority-assessed products (Morocco DMP, Tunisia DPM/ANPM, Egypt EDA, Saudi SFDA, Jordanian JFDA).
• Import-substitution policy implications — Ministry of Pharmaceutical Industry import-substitution policy progressively restricts imports where local manufacturing capacity exists; foreign manufacturers must plan for technology-transfer + local-manufacturing partnerships (frequently with SAIDAL or private Algerian manufacturers) for sustainable Algerian market access.
• Vital + Essential Medicines accelerated pathway not leveraged — accelerated Décision d'Enregistrement for Liste Nationale des Médicaments Essentiels + CNAS-procurement-priority products under-utilised; 90-120 working day target.
• Direction des Services Vétérinaires jurisdictional split — veterinary medicines + animal-origin foods sit with Direction des Services Vétérinaires under Ministry of Agriculture, not ANPP; avoid filing veterinary applications to ANPP.
• Ministry of Pharmaceutical Industry institutional position — ANPP's reporting to Ministry of Pharmaceutical Industry (rather than Ministry of Health) means industrial-policy considerations including import-substitution + export-orientation + technology-transfer significantly shape regulatory decisions + timelines.
• Variations strategy not planned — variations procedure substantively similar to EU but with Algeria-specific timelines + fee structure + French/Arabic-language requirements.
• Décision d'Enregistrement renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial CNESS + Law 18-11 steps — Algerian clinical trials require ANPP Autorisation d'Essai Clinique + Comité National d'Éthique des Sciences de la Santé (CNESS) approval; sponsors sometimes overlook CNESS recognition + multi-CHU clinical-trial coordination.
• Pharmacovigilance + CNPM gaps — ANPP BPPv requirements substantively similar to ICH E2 + EU GVP but with Algeria-specific CNPM integrated vigilance coordination + French + Arabic ICSR.

V5 Ultimate provides the operational infrastructure Algerian + foreign-supplier sites need for Law 18-11 of 2018 + Executive Decree 19-379 of 2019 + ANPP BPF + ANPP Medical Devices framework + AMRH + AMA + UMA + Union for the Mediterranean + Arab League + WHO PQ CRP + Algerian Pharmacovigilance Programme readiness.

• ANPP BPF control framework — PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Algeria-specific clarifications + Climate Zone II/IVa-IVb Saharan stability monitoring.
• ANPP Décision d'Enregistrement dossier packaging — Algerian CTD-aligned dossier structure with Algeria Module 1 specifics + Module 3 stability + French + Arabic notice patient + Représentant Autorisé declarations + Law 18-11 + Executive Decree 19-379 framework.
• AMRH / AMA workflow — AMRH co-Reference Authority + AMA Technical Committee packaging for joint assessment + reliance across African Member States.
• WHO PQ CRP workflow — ANPP-as-CRP-participating-authority packaging with reduced dossier + accelerated ANPP review (90-day target).
• EU / EMA / ANSM France reliance workflow — bilateral cooperation packaging reflecting Algeria's francophone + Mediterranean alignment.
• UMA workflow — Arab Maghreb Union pharmaceutical cooperation packaging alongside Morocco DMP + Tunisia DPM/ANPM + Libya NRA + Mauritania DPL.
• Union for the Mediterranean workflow — UfM regulatory cooperation packaging alongside EU Mediterranean Member States + Mediterranean Partner Countries.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging with Egyptian EDA + Saudi SFDA + Morocco DMP + Tunisia DPM/ANPM + Jordanian JFDA + UAE MoHAP coordination.
• Import-substitution + technology-transfer workflow — Ministry of Pharmaceutical Industry-coordinated local-manufacturing + technology-transfer + SAIDAL + private-domestic-manufacturer partnership packaging for sustainable Algerian market access.
• Vital + Essential Medicines accelerated workflow — Liste Nationale des Médicaments Essentiels + CNAS-procurement-priority product packaging with 90-120 working day accelerated review.
• Algerian Représentant Autorisé workflow — foreign-manufacturer Représentant Autorisé designation + role-management + Algeria-specific post-market surveillance + ANPP interface.
• Algerian clinical-trial workflow — ANPP Autorisation d'Essai Clinique + CNESS + multi-CHU coordination + Algerian SUSAR reporting via CNPM.
• ANPP/CNPM Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + French + Arabic ICSR + Réseau Algérien de Pharmacovigilance coordination + CNPM portal submission + VigiBase upload + Risk Management Plan packaging + MAPI vaccine adverse-event reporting.
• Matériovigilance + Réactovigilance + Cosmétovigilance workflow — parallel matériovigilance + IVD/reagent-vigilance + cosmétovigilance packaging coordinated through CNPM.
• Medical-device + IVD + reagent + cosmetic workflow — Law 18-11 + ANPP framework dossier packaging + Class I-III classification + ISO 13485 + Représentant Autorisé + post-market matériovigilance.
• AMRH + AMA + UMA + UfM + Arab League regional bridging — for companies operating across Africa + the Maghreb + the Mediterranean + the Arab World, V5 surfaces ANPP + Morocco DMP + Tunisia DPM/ANPM + Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Ethiopia EFDA harmonised dossier-element reuse alongside national-specific extensions.